NCT01634763View on ClinicalTrials.gov

Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)
Interventions
DRUG

LDK378

Trial Locations (3)

411-8777

Novartis Investigative Site, Sunto-gun

135-8550

Novartis Investigative Site, Koto

811-1395

Novartis Investigative Site, Fukuoka

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY